Catalyst Wire Dossier Catalyst Wire Dossier

Tuvoraleimab

tuvoraleimab
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tuvoraleimab, covering 2026-01-16 to 2026-01-16. Get the full timeline:

Most recent: Clinical Trial Update: Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma [Phase 2]

See pricing